These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8754442)

  • 1. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C; Maiques Galán A
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract]   [Full Text] [Related]  

  • 2. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Also elderly patients with hyperlipidemia and coronary disease need lipid lowering agents].
    Hellénius ML
    Lakartidningen; 2001 Sep; 98(39):4188-90. PubMed ID: 11680152
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement in current approaches to lipid lowering.
    Ansell BJ
    Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid lowering: myth or therapeutic necessity?].
    Dtsch Med Wochenschr; 1998 Oct; 123(40 Suppl):2-8. PubMed ID: 9793486
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):1Q-2Q. PubMed ID: 9819097
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholesterol and coronary artery disease--issues in the 1990s.
    Chia BL
    Singapore Med J; 1991 Oct; 32(5):291-4. PubMed ID: 1788566
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
    Haffner SM; Ashraf T
    Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
    Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
    CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
    [No Abstract]   [Full Text] [Related]  

  • 13. [Analysis of reasons for discontinuation of treatment for dyslipidemia in secondary prevention of coronary heart disease].
    Tyszecka G
    Przegl Lek; 1999; 56(11):709-15. PubMed ID: 10800583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia and coronary artery disease.
    Genest JG
    Can J Cardiol; 2000 Jan; 16 Suppl A():3A-4A. PubMed ID: 10653923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of lipemia-lowering agents in the secondary prevention of myocardial infarct].
    Tullio D
    Clin Ter; 1986 Feb; 116(3):221-35. PubMed ID: 3516543
    [No Abstract]   [Full Text] [Related]  

  • 17. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hyperlipidemia, coronary disease and antilipemic drugs--do they help?].
    Hansteen V
    Tidsskr Nor Laegeforen; 1995 Nov; 115(29):3602-3. PubMed ID: 8539711
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D; Davis R
    Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.